Search Results
Feb 26, 2026, 15:17 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Feb 24, 2026, 17:17 ET CME Group U.S. Treasury Open Interest Surges to Record High of 36.3 Million Contracts
environment."Additional OI records across the yield curve include:Record 2-Year U.S. Treasury Note futures and options OI of 5.8 million contractsRecord 5-Year U.S. Treasury Note futures OI of 7.9 million contractsRecord 10-Year U.S. Treasury Note futures and options OI of 12.6
More news about: CME Group
Feb 23, 2026, 04:06 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
gave investors a falsely optimistic impression of its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta ("OI"). The Company's failures were revealed by the Phase III ORBIT study in which it failed to achieve a statistically significant reduction in annualized
More news about: The Schall Law Firm
Feb 20, 2026, 10:26 ET RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Feb 19, 2026, 20:04 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Feb 19, 2026, 20:04 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Feb 19, 2026, 12:20 ET INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - RARE
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Robbins Geller Rudman & Dowd LLP
Feb 18, 2026, 18:09 ET Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately
misleading statements about the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta (OI).Specifically, defendants repeatedly expressed confidence that:The ORBIT and COSMIC Phase 3 trials wouldAchieve
More news about: Wolf Haldenstein Adler Freeman & Herz LLP
Feb 17, 2026, 06:50 ET Labcorp Announces 2025 Fourth Quarter and Full Year Results
Operating Income ("OI")$ 267.6
More news about: Labcorp Holdings Inc
Feb 16, 2026, 20:59 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P.A.
Feb 16, 2026, 20:30 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Feb 14, 2026, 11:23 ET Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately
misleading statements about the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta (OI).Specifically, defendants repeatedly expressed confidence that:The ORBIT and COSMIC Phase 3 trials wouldAchieve
More news about: Wolf Haldenstein Adler Freeman & Herz LLP
Feb 12, 2026, 18:51 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Feb 12, 2026, 18:42 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Feb 11, 2026, 22:06 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P. A.
Feb 11, 2026, 20:24 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Feb 11, 2026, 09:06 ET RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Feb 10, 2026, 12:37 ET CME Group to Launch Single Stock Futures
Futures and options average daily volume (ADV) of 7.4 million contracts and open interest (OI) of 9.8 million contracts.Futures ADV of 6 million contracts, up 15% year-over-year, and record average OI of 5.6 million contracts, up 19% year-over-year.The contracts will be listed on
More news about: CME Group
Feb 10, 2026, 07:10 ET INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - RARE
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Robbins Geller Rudman & Dowd LLP
Feb 09, 2026, 03:25 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
gave investors a falsely optimistic impression of its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta ("OI"). The Company's failures were revealed by the Phase III ORBIT study in which it failed to achieve a statistically significant reduction in annualized
More news about: The Schall Law Firm
Feb 06, 2026, 08:49 ET RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Feb 06, 2026, 02:01 ET MREO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Mereo BioPharma Group plc
investors with material information concerning their expected results for the Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: Robbins LLP
Feb 06, 2026, 02:00 ET RARE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Ultragenyx Pharmaceutical Inc.
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: Robbins LLP
Feb 05, 2026, 07:20 ET INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Robbins Geller Rudman & Dowd LLP
Jan 27, 2026, 16:01 ET TI reports Q4 2025 and 2025 financial results and shareholder returns
5,465Other income (expense), net (OI&E)
More news about: Texas Instruments Incorporated